92 related articles for article (PubMed ID: 34590027)
1.
von Buttlar X; Reuss JE; Liu SV; Kim C
JTO Clin Res Rep; 2021 Jun; 2(6):100179. PubMed ID: 34590027
[TBL] [Abstract][Full Text] [Related]
2. Successful management of a lung cancer patient harbouring both
Fujita K; Naka M; Ito T; Kanai O; Maekawa K; Nakatani K; Mio T
Respir Med Case Rep; 2021; 33():101393. PubMed ID: 33854939
[TBL] [Abstract][Full Text] [Related]
3. Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
Zhang L; Li Y; Zhang S; Gao C; Nie K; Ji Y
Cancer Biol Med; 2018 May; 15(2):178-181. PubMed ID: 29951342
[TBL] [Abstract][Full Text] [Related]
4. Response to erlotinib in a patient with lung adenocarcinoma harbouring the
Alì G; Chella A; Lupi C; Proietti A; Niccoli C; Boldrini L; Davini F; Mussi A; Fontanini G
Oncol Lett; 2015 Apr; 9(4):1537-1540. PubMed ID: 25788996
[TBL] [Abstract][Full Text] [Related]
5. Potential Therapeutic Strategy for
Huang MH; Lee JH; Hung PS; Chih-Hsin Yang J
JTO Clin Res Rep; 2022 Nov; 3(11):100405. PubMed ID: 36325153
[TBL] [Abstract][Full Text] [Related]
6.
Zeng Z; Wang T; He J; Wang Y
Front Oncol; 2022; 12():1010084. PubMed ID: 36387181
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib and Capmatinib Combination Therapy to Overcome
Wilgucki M; Yeung V; Ho G; Bravo Montenegro GL; Jones G; Reuss JE; Liu SV; Kim C
JTO Clin Res Rep; 2022 Oct; 3(10):100396. PubMed ID: 36188633
[TBL] [Abstract][Full Text] [Related]
8. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.
Doval D; Prabhash K; Patil S; Chaturvedi H; Goswami C; Vaid A; Desai S; Dutt S; Veldore V; Jambhekar N; Mehta A; Hazarika D; Azam S; Gawande S; Gupta S
Onco Targets Ther; 2015; 8():117-23. PubMed ID: 25609979
[TBL] [Abstract][Full Text] [Related]
9. A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib.
Inoue Y; Matsubara O; Ohira Y; Endo S; Jinn Y
Respir Med Case Rep; 2021; 33():101418. PubMed ID: 34401266
[TBL] [Abstract][Full Text] [Related]
10. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
Tani T; Yasuda H; Hamamoto J; Kuroda A; Arai D; Ishioka K; Ohgino K; Miyawaki M; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Ther; 2016 Jan; 15(1):162-71. PubMed ID: 26682573
[TBL] [Abstract][Full Text] [Related]
11. Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation.
Nguyen THT; Pham XD; Dao KL; Vo TT
Case Rep Oncol; 2021; 14(2):1085-1091. PubMed ID: 34326746
[TBL] [Abstract][Full Text] [Related]
12. Frequency, clinical features and differential response to therapy of concurrent
Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
[No Abstract] [Full Text] [Related]
13. A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
Xu X; Liu D; Wen J; Chen J; Fan M
Transl Lung Cancer Res; 2020 Dec; 9(6):2500-2507. PubMed ID: 33489810
[TBL] [Abstract][Full Text] [Related]
14. Targeting
Aboubakar Nana F; Ocak S
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
[TBL] [Abstract][Full Text] [Related]
15. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma.
Kang HJ; Lim HJ; Park JS; Cho YJ; Yoon HI; Chung JH; Lee JH; Lee CT
Respir Med; 2014 Feb; 108(2):388-94. PubMed ID: 24361161
[TBL] [Abstract][Full Text] [Related]
17. Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance
Zhu Y; Jia R; Shao YW; Zhu L; Ou Q; Yu M; Wu X; Zhang Y
Front Oncol; 2020; 10():1259. PubMed ID: 32850382
[No Abstract] [Full Text] [Related]
18. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
19. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
Matsuda H; Hara M; Iwakami SI; Takahashi K
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33906872
[TBL] [Abstract][Full Text] [Related]
20. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]